Research programme: glutamate receptor modulators - Eli Lilly

Drug Profile

Research programme: glutamate receptor modulators - Eli Lilly

Alternative Names: GluR5 kainate receptor antagonists - Eli Lilly; LY 503430; LY-2607540; LY-450108

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Isoquinolines
  • Mechanism of Action AMPA receptor agonists; Kainic acid receptor antagonists; Metabotropic glutamate receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Anxiety disorders; Cognition disorders; Major depressive disorder; Mood disorders; Pain; Parkinson's disease; Schizophrenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Anxiety-disorders in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top